JBIO: JADE101’s quarterly dosing and potent IgA reduction position it as a leading therapy in IgAN
The company is advancing three main assets targeting autoimmune diseases, with JADE101 showing strong phase I results in IgA nephropathy and moving rapidly into phase II and III. Differentiation is based on potency, dosing convenience, and safety, with a robust financial position supporting progres…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.